Potential of IL-33 for Preventing the Kidney Injury via Regulating the Lipid Metabolism in Gout Patients

Abstract EN

Interleukin-33 (IL-33), the most recently discovered member of the IL-1 superfamily, has been linked to several human pathologies including autoimmune diseases, sepsis, and allergy through its specific IL-1 receptor ST2.

However, there is little information regarding the role of IL-33 in gout.

In this study, we investigated the potential role of IL-33 in gout patients.

The serum level of IL-33 was measured by ELISA, and the clinical and laboratory parameters, serum creatinine, urea, and lipid, were extracted from medical record system.

The serum IL-33 expression was predominantly increased in gout patients compared to healthy controls, and the IL-33 levels were higher in patients without kidney injury.

Furthermore, IL-33 showed a negative correlation with biomarkers of kidney injury, such as CRE and urea.

The lipid metabolism dysfunction, tophi, and hypertension are the common reasons for kidney injury in gout.

Interestingly, inverse and positive correlation of IL-33 expression was observed in LDL and HDL, respectively.

However, there was no significant alteration in the gout patients with hypertension and tophi.

These data suggested that IL-33 might act as a protective role in kidney injury through regulating the lipid metabolism in gout.